TipRanks
Go Ultimate55% OFF

Veraxa Biotech (VRXA) Financial Statements

Veraxa Biotech Financial Overview

Veraxa Biotech's market cap is currently $168.42M. The company's EPS TTM is $0.25; its P/E ratio is 50.75; Veraxa Biotech has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24
Income Statement
Total Revenue$ 0.00$ 0.00
Gross Profit$ 0.00$ 0.00
Operating Income$ -1.79M$ -702.96K
EBITDA$ -1.79M$ -702.96K
Net Income$ 8.99M$ 4.14M
Balance Sheet
Cash & Short-Term Investments$ 182.10K$ 668.28K
Total Assets$ 270.06M$ 259.81M
Total Debt$ 0.00$ 0.00
Net Debt$ -182.10K$ -668.28K
Total Liabilities$ 13.34M$ 12.08M
Stockholders' Equity$ 256.72M$ 247.73M
Cash Flow
Free Cash Flow$ -486.18K$ -703.47K
Operating Cash Flow$ -486.18K$ -703.47K
Investing Cash Flow$ 0.00$ -254.26M
Financing Cash Flow$ 0.00$ 255.64M

Currency in USD

Veraxa Biotech Earnings and Revenue History

04M8M12M0 %0.4 %0.8 %1.2 %EarningsProfit Margin20242025RevenueEarningsProfit Margin

Veraxa Biotech Debt to Assets

0100M200M300M4.6 %4.8 %5 %5.2 %LiabilitiesDebt to Assets20242025AssetsLiabilitiesDebt to Assets

Veraxa Biotech Cash Flow

-300M-200M-100M0100M200M300M20242025OperatingInvestingFinancing

Veraxa Biotech Forecast EPS vs Actual EPS